<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Andexanet alfa (inactivated coagulation factor Xa [recombinant]): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Andexanet alfa (inactivated coagulation factor Xa [recombinant]): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Andexanet alfa (inactivated coagulation factor Xa [recombinant]): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="117870" href="/d/html/117870.html" rel="external">see "Andexanet alfa (inactivated coagulation factor Xa [recombinant]): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F51391990"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic risks, ischemic risks, cardiac arrest, and sudden deaths:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment with andexanet alfa has been associated with serious and life-threatening adverse events, including: Arterial and venous thromboembolic events, ischemic events (including myocardial infarction and ischemic stroke), cardiac arrest, and sudden deaths. Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51450252"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Andexxa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51391997"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F51450411"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6abdcb7-8b1b-4613-808c-6d81b54caf0f">Life-threatening bleeding associated with factor Xa inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Life-threatening bleeding associated with factor Xa inhibitors: </b>
<b>Note:</b> Generally used for life-threatening bleeding or bleeding into a critical organ that is not controlled with maximal supportive measures (eg, activated charcoal [if ingestion is within ~2 to 4 hours], antifibrinolytic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Life-threatening bleeding associated with edoxaban or betrixaban (off-label use):</i> IV: </b>800 mg IV bolus administered at a rate of ~30 mg/minute, followed within 2 minutes by an IV infusion of 8 mg/minute for up to 120 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Life-threatening bleeding associated with apixaban or rivaroxaban:</b></i>
<b>Note:</b> Safety and efficacy of &gt;1 dose of andexanet alfa has not been established. Resume anticoagulant therapy as soon as medically appropriate following treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Low dose:</i> 400 mg IV bolus administered at a rate of ~30 mg/minute, followed within 2 minutes by an IV infusion of 4 mg/minute for up to 120 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>High dose:</i> 800 mg IV bolus administered at a rate of ~30 mg/minute, followed within 2 minutes by an IV infusion of 8 mg/minute for up to 120 minutes.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="4">
<p style="text-indent:0em;">Andexanet alfa Dose Based on Apixaban or Rivaroxaban Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Factor Xa Inhibitor</b></p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Factor Xa Inhibitor Last Dose</b></p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<b>Timing of Factor Xa Inhibitor Last Dose Before Andexanet alfa Initiation</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>&lt;8 Hours or Unknown</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>≥8 Hours</b></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Apixaban</b></p></td>
<td align="center">
<p style="text-indent:0em;">≤5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Low dose</p></td>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Low dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;5 mg or unknown</p></td>
<td align="center">
<p style="text-indent:0em;">High dose</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Rivaroxaban</b></p></td>
<td align="center">
<p style="text-indent:0em;">≤10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">Low dose</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;10 mg or unknown</p></td>
<td align="center">
<p style="text-indent:0em;">High dose</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F51450417"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F51450418"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F51450416"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51450678"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (6% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis (6%), ischemic stroke (5%), acute myocardial infarction (3%), pulmonary embolism (3%), cardiogenic shock (2%), cardiac failure (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (≥5%), acute respiratory failure (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Arterial thromboembolism, venous thromboembolism</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Coronary thrombosis, intracardiac thrombus, nonsustained ventricular tachycardia</p></div>
<div class="block coi drugH1Div" id="F51391994"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F51450401"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anti-factor Xa activity re-elevation: There is a rapid and substantial decrease in anti-factor Xa activity corresponding to the bolus dose, which is sustained during the continuous infusion. Anti-factor Xa activity returns to levels seen in patients receiving placebo ~2 hours after completion of bolus or continuous infusion; thereafter, anti-factor Xa activity decreases at a rate similar to the clearance of factor Xa inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic and ischemic risks: Arterial and venous thromboembolic events, ischemic events, and cardiac events (including sudden death) were observed within 3 to 30 days postadministration (median time to first event: 7 days). Monitor patients for signs and symptoms of arterial and venous thromboembolic events, ischemic events, and cardiac arrest. To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following treatment with andexanet alfa. Safety has not been evaluated in patients with thromboembolic events or disseminated intravascular coagulation within 2 weeks prior to the bleeding event or in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within 7 days prior to the bleeding event.</p></div>
<div class="block foc drugH1Div" id="F51450253"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Andexxa: 200 mg (1 ea) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Andexxa: 200 mg (1 ea [DSC]) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F51450251"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51450730"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Andexxa Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3,000.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F51450419"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration. Initiate bolus at a target rate of ~30 mg/minute. For IV infusion, use of a 0.2 or 0.22 micron in-line polyethersulfone or equivalent low protein-binding filter is required.</p></div>
<div class="block use drugH1Div" id="F51391993"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Life-threatening bleeding associated with apixaban or rivaroxaban: </b>Reversal of anticoagulation in patients treated with apixaban or rivaroxaban experiencing life-threatening or uncontrolled bleeding.</p></div>
<div class="block off-label drugH1Div" id="F51992827"><span class="drugH1">Use: Off-Label: Adult</span><p>Life-threatening bleeding associated with edoxaban or betrixaban</p></div>
<div class="block cyt drugH1Div" id="F51502238"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51502235"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Andexanet Alfa (Coagulation Factor Xa [Recombinant], Inactivated) may diminish the therapeutic effect of Heparin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F51450395"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F51450396"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if andexanet alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F51450421"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Signs/symptoms of arterial and venous thromboembolic events, ischemic events, or cardiac arrest</p>
<p style="text-indent:-2em;margin-left:2em;">Signs/symptoms of hemostasis; if available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is anti-factor Xa activity individually calibrated to each specific factor Xa inhibitor (undetectable anti-factor Xa activity likely excludes clinically relevant drug concentrations). An anti-factor Xa activity assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations of a factor Xa inhibitor DOAC but is not useful for quantification (ACC [Tomaselli 2020]; AHA [Raval 2017]).</p></div>
<div class="block pha drugH1Div" id="F51450405"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Andexanet alfa binds and sequesters the factor Xa inhibitors rivaroxaban and apixaban. In addition, andexanet alfa inhibits the activity of Tissue Factor Pathway Inhibitor, increasing tissue factor-initiated thrombin generation.</p></div>
<div class="block phk drugH1Div" id="F51450406"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Rapid (Lu 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Generation 1 product: Low dose: 5.1 (range: 3.2 to 13.8) L; High dose: 4.1 (range: 2.4 to 5.7) L</p>
<p style="text-indent:-2em;margin-left:4em;">Generation 2 product: Low dose: 4.4 (range: 3.3 to 5.7) L; High dose: 3 (range 2.2 to 5) L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: <b>Note</b>: Clinical trials have shown that when andexanet alfa is administered to patients taking apixaban or rivaroxaban, anti-factor Xa activity increases to levels seen in patients receiving placebo ~2 hours after completion of the infusion (Connolly 2016; Siegal 2015). However, elevation of tissue factor-initiated thrombin generation above pretreatment baseline occurs within 2 minutes after administration and is sustained above placebo for at least 22 hours after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Pharmacokinetic half-life:</p>
<p style="text-indent:-2em;margin-left:6em;">Generation 1 product: Low dose: 4.3 (range: 3.3 to 11.9) hours; High dose: 4 (range: 2 to 5.7) hours</p>
<p style="text-indent:-2em;margin-left:6em;">Generation 2 product: Low dose: 3.3 (range: 2.3 to 4) hours; High dose: 2.7 (range: 1.9 to 3.4) hours</p>
<p style="text-indent:-2em;margin-left:4em;">Pharmacodynamic half-life: ~1 hour (Siegal 2015).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53550906"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Andexxa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ondexxya</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Andexxa.1">
<a name="Andexxa.1"></a>Andexxa (andexanet alfa) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31732375">
<a name="31732375"></a>Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. <i>Ann Emerg Med</i>. 2019;S0196-0644(19)31181-31183. doi:10.1016/j.annemergmed.2019.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/31732375/pubmed" id="31732375" target="_blank">31732375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34996121">
<a name="34996121"></a>Benz AP, Xu L, Eikelboom JW, et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban.<i> Thromb Haemost.</i> 2022;122(6):998-1005. doi:10.1055/s-0041-1740180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/34996121/pubmed" id="34996121" target="_blank">34996121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27573206">
<a name="27573206"></a>Connolly SJ, Milling TJ Jr, Eikelboom JW, et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. <i>N Engl J Med</i>. 2016;375(12):1131-1141. doi:10.1056/NEJMoa1607887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/27573206/pubmed" id="27573206" target="_blank">27573206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowther.2016">
<a name="Crowther.2016"></a>Crowther M, Levy GG, Lu G, et al. Reversal of betrixaban-induced anticoagulation in healthy volunteers by andexanet alfa. <i>Blood</i>. 2016;128(22):143. http://www.bloodjournal.org/content/128/22/143. Accessed September 28, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowther.2014">
<a name="Crowther.2014"></a>Crowther M, Levy GG, Lu G, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. <i>Blood</i>. 2014;124(21):4269. http://www.bloodjournal.org/content/124/21/4269.abstract. Accessed September 28, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916798">
<a name="30916798"></a>Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. <i>Am J Hematol</i>. 2019;94(6):697-709. doi:10.1002/ajh.25475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/30916798/pubmed" id="30916798" target="_blank">30916798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23455714">
<a name="23455714"></a>Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. <i>Nat Med</i>. 2013;19(4):446-451. doi:10.1038/nm.3102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/23455714/pubmed" id="23455714" target="_blank">23455714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36802876">
<a name="36802876"></a>Milling TJ Jr, Middeldorp S, Xu L, et al; ANNEXA-4 Investigators. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. <i>Circulation</i>. 2023;147(13):1026-1038. doi:10.1161/CIRCULATIONAHA.121.057844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/36802876/pubmed" id="36802876" target="_blank">36802876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28167634">
<a name="28167634"></a>Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published correction appears in: <i>Circulation</i>. 2017;135(10 ):e647. <i>Circulation</i>. 2017;135(24):e1144.]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/28167634/pubmed" id="28167634" target="_blank">28167634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26559317">
<a name="26559317"></a>Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity.<i> N Engl J Med</i>. 2015;373(25):2413-2424. doi:10.1056/NEJMoa1510991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/26559317/pubmed" id="26559317" target="_blank">26559317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/andexanet-alfa-inactivated-coagulation-factor-xa-recombinant-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117811 Version 82.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
